Connor, Clark & Lunn Investment Management Ltd. I Mab Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$21.8 Billion
Q1 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2023 Nov 13, 2023	BUY	$1.18 - $3.06 $27,894 - $72,335	23,639 New	23,639 $31,000
Q4 2022 Feb 10, 2023	BUY	$3.22 - $4.86 $87,303 - $131,769	27,113 New	27,113 $113,000

Others Institutions Holding IMAB

# of Institutions

Shares Held

16M

Call Options Held

11.9K

Put Options Held

3.5K

Hhlr Advisors, Ltd. Grand Cayman, E9

6.91M
Shares

$10.9 Million
0.29% of portfolio
Decheng Capital Management Iii (Cayman), LLC

4.17M
Shares

$6.58 Million
3.04% of portfolio
David A. Siegel Two Sigma Advisers, LP | New York, Ny

617K
Shares

$975,018
0.0% of portfolio
Two Sigma Investments, LP New York, NY

576K
Shares

$909,416
0.0% of portfolio
Temasek Holdings (Private) LTD Singapore, U0

567K
Shares

$895,307
0.01% of portfolio

View Full List

About I-Mab

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $131M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

More about IMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account